RESEARCH ARTICLE

Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy

Issei Saeki¹, Takahiro Yamasaki²*, Masaki Maeda¹, Takuro Hisanaga¹,³, Takuya Iwamoto¹, Toshihiko Matsumoto¹,², Isao Hidaka¹, Tsuyoshi Ishikawa¹, Taro Takami¹, Isao Sakaida¹

¹ Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan, ² Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan, ³ Department of Medical Education, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan

* t.yama@yamaguchi-u.ac.jp

Abstract

Aim

Sorafenib is used as a first-line treatment for advanced hepatocellular carcinoma (HCC). However, hepatic arterial infusion chemotherapy (HAIC) has also gained acceptance, but only in Japan. We explored the role of body composition as a factor affecting the survival benefit of HAIC compared to sorafenib for the treatment of advanced HCC.

Methods

We conducted a retrospective study using the clinical records of 133 patients with advanced HCC treated either with HAIC or sorafenib. Prior to treatment induction, skeletal muscle index and visceral fat area (VFA) were measured at the third lumbar vertebral and umbilical levels, respectively, using computed tomography. Muscle depletion and high-VFA (H-VFA) were defined using published cut-offs. We analyzed clinical parameters, including body composition as prognostic factors.

Results

In the HAIC group, multivariate analysis identified a positive response to HAIC (hazard ratio [HR], 0.438; p = 0.022), and conversion from HAIC to sorafenib (HR, 0.374; p = 0.008) as favorable prognostic factors for survival. In contrast, tumor number < 7 (HR, 0.475; p = 0.008), absence of extra-hepatic spread (HR, 0.511; p = 0.015), absence of muscle depletion (HR, 0.555; p = 0.044), and H-VFA (HR, 0.483; p = 0.015) were studied in the sorafenib group.
Conclusions

Body composition was identified as a prognostic factor for patient survival after treatment with sorafenib, but not for HAIC, and may be used as a biomarker when selecting between HAIC or sorafenib treatment of patients with advanced HCC. Additionally, conversion to sorafenib in patients receiving HAIC could improve survival regardless of response status.

Introduction

Hepatocellular carcinoma (HCC) is the most common cause of liver cancer and the fourth most frequent cause of death in the world [1]. The number of primary liver cancer cases, of which HCC accounts for 75–85%, is expected to increase globally by 2030 [2]; however, of the 30 modeled countries, only Japan is predicted to decline in liver cancer incidence. In contrast, the number of patients with HCC who test negative for both hepatitis B surface antigen and hepatitis C virus antibody is increasing in Japan [3, 4], which is problematic as these patients are not adequately screened and, therefore, the disease is not diagnosed until it has reached late stages [5]. Furthermore, many patients who have received curative therapies such as surgical resection or local ablation subsequently develop recurrent disease which is often advanced.

Presently, the first-line treatment strategy for patients with advanced HCC is the administration of sorafenib according to several guidelines from Japan, Europe, and the United States [6–10]; however, hepatic arterial infusion chemotherapy (HAIC) is also widely used throughout Asia, especially in Japan. Indeed, Japan is the only country that recommends HAIC as standard therapy in the treatment algorithm [9, 10]. A Japanese nation-wide survey, which highlighted the efficacy of HAIC for treatment of advanced HCC, demonstrated that patients treated with HAIC using a low-dose of cisplatin (CDDP) and 5-fluorouracil (5-FU, FP) exhibited a significantly longer median survival time (MST) than patients who did not receive active treatment (14.0 versus 5.2 months; \( p < 0.0001 \)) [11].

To date, no randomized controlled trials have established a guideline for clinicians to select either sorafenib or HAIC for the management of advanced HCC. Considering the poor prognosis associated with advanced HCC, the identification of patients likely to benefit from either sorafenib or HAIC is important.

A number of prognostic factors have been identified for various malignancies, including the patient’s skeletal muscle and visceral fat composition [12]. In fact, reports of patients treated with sorafenib for HCC suggested that skeletal muscle depletion was an independent prognostic factor [13–15]. We recently determined that the lack of skeletal muscle depletion with a high visceral fat area (H-VFA) was a favorable prognostic predictor for the survival of sorafenib-treated advanced HCC patients [16]. However, there are no studies of body composition in HAIC treated HCC patients. In addition, there is inconclusive evidence for whether therapeutic conversion (conversion from HAIC to sorafenib, or sorafenib to HAIC) provides a considerable survival benefit.

In this study, we retrospectively analyzed the impact of body composition and therapeutic conversion on the clinical outcome of patients with advanced HCC treated with HAIC or sorafenib. Also, we investigated factors that would identify patients likely to respond to treatment with HAIC or sorafenib.

Materials and methods

Study design and patient selection

This study complied with the ethical principles of the Declaration of Helsinki. The Institutional Review Board of Yamaguchi University Hospital approved the research protocol (H28-
This was a retrospective patient record study conducted at Yamaguchi University Hospital, and the informed consent was waived. All records were obtained as anonymized data.

This study began after sorafenib was approved for use in Japan. Records of patients diagnosed with advanced stage HCC between April 2009 and December 2016 were reviewed for study inclusion by a clinician. Patient records were selected if either HAIC or sorafenib was administered as a first line treatment for advanced HCC, which was untreatable by loco-regional therapies, including hepatectomy, radiofrequency ablation, or transcatheter arterial chemoembolization (TACE).

According to Japanese guidelines [9, 17, 18], in general, HAIC and sorafenib were recommended for cases with macrovascular invasion (MVI) and extra-hepatic spread (EHS), respectively. The diagnosis of HCC was based on imaging results and elevated serum levels of alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), or both [19]. Patient records without computed tomography (CT) within 1 month of starting HAIC or sorafenib were excluded; if no CT image slices were available to assess body composition, magnetic resonance imaging (MRI) was used. Out of 133 reviewed records, 55 and 78 patients who were treated with HAIC and sorafenib, respectively, were included in the analysis (Fig 1). The follow-up period ended on December 31, 2017.

Data on age, sex, Child-Pugh classification, tumor number and maximum size, MVI, EHS, radiological response, muscle depletion, and visceral fat area (VFA) were collected for each patient. Information on therapeutic conversion from HAIC to sorafenib, or from sorafenib to HAIC was also collected.

**HAIC and sorafenib therapy.** For HAIC administration, a 5-French catheter (Anthron P-U Catheter; Toray Medical Co. Ltd., Tokyo, Japan; or Piolax, G-spiral catheter; Piolax, Kanagawa, Japan) was inserted in the gastroduodenal artery or proper hepatic artery and connected to the port. All patients received HAIC with a low-dose of FP and isovorin [20]. In brief, patients received a daily low-dose of FP, including CDDP (10 mg/body), followed by 5-FU (250 mg/body), and isovorin (6.25 mg/body) once daily on days 1–5. One course of HAIC consisted of 20 doses.

The initial dose of sorafenib was 800 mg. However, when adverse effects during the treatment course occurred, the dose was reduced. Furthermore, the initial dose was started from 400 mg depending on the liver function. The initial evaluation was performed 8 to 12 weeks later.

**Assessment of body composition**

We evaluated body composition using CT images obtained within 1 month prior to introducing treatment with HAIC or sorafenib and 3 months after each treatment. The areas of skeletal
muscle and visceral fat were measured using an AZE 3D work station (AZE-3DWS, AZE Virtual Place Raijin, AZE Ltd., Tokyo, Japan). Specifically, the skeletal muscle area and VFA were measured using a CT scan at the third lumbar vertebra level (L3), and at the umbilical level, respectively. Skeletal muscle and visceral fat were quantified using Hounsfield unit (HU) thresholds of –29 to 150 [21], and –190 to –30 [22], respectively. The skeletal muscle mass was normalized to height (m$^2$) and was expressed as the skeletal muscle index (SMI, cm$^2$/m$^2$).

Using these values for SMI, muscle depletion was defined as < 42 cm$^2$/m$^2$ in men and < 38 cm$^2$/m$^2$ in women, in accordance with the Japan Society of Hepatology (JSH) criteria [23]. The cut-off value of VFA, following the criteria for obesity established by the Japan Society for the Study of Obesity (JASSO), was set to 100 cm$^2$, and H-VFA was defined as ≥ 100 cm$^2$ in men and women [24].

**Evaluation of treatment response**

The evaluation of treatment response was performed with dynamic CT or MRI and classified according to the modified response evaluation criteria in solid tumors [25]. The response was evaluated after one course of HAIC, and every 3 months in the group receiving sorafenib. A subset of patients who were not evaluated for treatment response according to imaging, was designated as no evaluation (NE). The positive response and positive disease control were defined as the sum of complete response (CR) and partial response (PR), and the sum of CR, PR, and stable disease (SD), respectively.

**Statistical analysis**

Continuous variables were presented as the means ± standard deviation or median (interquartile range [IQR]) and compared using a paired or unpaired $t$-test. Categorical variables were evaluated using the chi-squared test or Fisher’s exact test. The overall survival (OS) was estimated by the Kaplan-Meier method and compared using the log-rank test. The clinical prognostic factors that were assessed in the survival analysis, included age (< 70 or ≥ 70 years), sex (male or female), Child-Pugh classification (A or B), tumor number (< 10 or ≥ 10 in the HAIC group, < 7 or ≥ 7 in the sorafenib group), maximum tumor size (< 70 mm or ≥ 70 mm in the HAIC group, < 40 mm or ≥ 40 mm in the sorafenib group), MVI (absence/presence), EHS (absence/presence), muscle depletion (absence/presence), and VFA (H-VFA or low VFA [L-VFA]). Radiological evaluation response was positive or negative in the HAIC and sorafenib groups, and disease control was denominated as positive/negative in the latter group as well. Also, the therapeutic conversion was defined as yes or no for both HAIC and sorafenib groups. The cut-off values of number and size of tumors are presented as medians. A Cox regression model was used to analyze the factors associated with OS, and the results are presented as hazard ratio (HR) with 95% confidence intervals (CIs). A $p$-value < 0.05 was considered statistically significant. All analyses were performed in the JMP software package v13.0 (SAS Institute, Cary, NC, USA).

**Results**

**Patient characteristics**

The clinical patient characteristics are summarized in Table 1. Fifty-five individuals were treated with HAIC and mean patient age was 66.7 ± 11.4 years. Liver function was Child-Pugh class A in 36 patients and class B in 19 patients. The median number and maximum size of tumors were > 10 and 71.0 mm, respectively. Forty-six patients had MVI and eight showed
EHS. Twenty-six patients converted from HAIC to sorafenib as a post-treatment. Muscle depletion was observed in 24 patients (43.6%) and H-VFA was detected in 34 patients (61.8%). In contrast, 78 individuals were treated with sorafenib and had a mean age of 72.2 ± 8.5 years. Liver function was Child-Pugh class A in 60 patients and class B in 18. The median number and maximum size of tumors were 6.5 and 40.0 mm, respectively, while 15 patients had MVI and 36 showed EHS. Six patients converted from sorafenib to HAIC as a post-treatment. Muscle depletion was observed in 32 patients (41.0%), and H-VFA was detected in 52 patients (66.7%).

There were significant differences in age, tumor number, maximum tumor size, MVI, and EHS between the two groups because of selection bias. The HAIC group had significantly higher number of tumors (median, 10.0; \( p = 0.015 \)), larger maximum tumor size (median, 71.0 mm; \( p < 0.001 \)), and higher proportion of patients with MVI (83.6%; \( p < 0.001 \)) than the sorafenib group. Whereas, the sorafenib group had significantly older (mean, 72.2 years; \( p = 0.002 \)), and higher proportion of patients with EHS (46.2%; \( p < 0.001 \)).

**Response to HAIC and sorafenib**

The responses to HAIC and sorafenib are summarized in S1 Table. In the HAIC group, 2 (3.6%), 14 (25.5%), 22 (40.0%), and 16 (29.1%) patients exhibited CR, PR, SD, and progressive

| Table 1. Patient characteristics. | HAIC (N = 55) | Sorafenib (N = 78) | p value |
|----------------------------------|---------------|-------------------|---------|
| **Age**                          | 66.7 ± 11.4   | 72.2 ± 8.5        | 0.002   |
| **Sex (M/F)**                    | 42 (76.4)/13 (23.6) | 57 (73.1)/21 (26.9) | 0.692   |
| **Etiology (C/B/Alc/N)**         | 21 (38.1)/16 (29.1)/10 (18.2)/8 (14.6) | 46 (59.0)/12 (15.4)/10 (12.8)/10 (12.8) | 0.096   |
| **Child-Pugh class (A/B)**       | 36 (65.5)/19 (34.5) | 60 (76.9)/18 (23.1) | 0.171   |
| **Tumor number**                 | >10.0 (6.0–>10.0) | 6.5 (3.0–>10.0) | 0.015   |
| **Tumor size [mm]**              | 71.0 (40.0–100.0) | 40.0 (22.8–61.5) | <0.001  |
| **MVI (absence/presence)**       | 9 (16.4)/46 (83.6) | 63 (80.8)/15 (19.2) | <0.001  |
| **EHS (absence/presence)**       | 47 (85.5)/8 (14.5) | 42 (53.8)/36 (46.2) | <0.001  |
| **Conversion to sorafenib (yes/no)** | 26 (47.3)/29 (52.7) | - | - |
| **Conversion to HAIC (yes/no)**  | - | 6 (7.7)/72 (92.3) | - |
| **L3 SMI**                       | M 44.2 ± 5.2  | 44.4 ± 7.7   | 0.888   |
| **F 35.6 ± 6.5**                 | 37.9 ± 5.2 | 37.9 ± 5.2 | 0.280   |
| **VFA**                          | 119.9 (78.2–180.3) | 119.5 (83.8–158.3) | 0.880   |
| **Muscle depletion**             | 31 (56.4)/24 (43.6) | 46 (59.0)/32 (41.0) | 0.859   |
| * (absence/presence)             | - | - | - |
| **VFA**                          | 34 (61.8)/21 (38.2) | 52 (66.7)/26 (33.3) | 0.585   |
| **VFA**                          | 34 (61.8)/21 (38.2) | 52 (66.7)/26 (33.3) | 0.585   |

Values are number (%), expressed mean ± standard deviation or median (interquartile ranges)

M, Male; F, Female; C, Hepatitis C virus; B, Hepatitis B virus; Alc, Alcohol; N, Non-B, non-C; MVI, Macrovascular invasion; EHS, Extrahepatic spread; SMI, Skeletal muscle index; VFA, Viscera fat area

* According to the criteria of Japan Society of Hepatology

b According to the criteria for ‘obesity disease’ as established by the Japan Society for the Study of Obesity

https://doi.org/10.1371/journal.pone.0218136.t001
disease (PD), while NE was found in one (1.8%) patient. Thus, the response and disease control rates were 29.6% and 70.4%, respectively. On the other hand, in the sorafenib group, 0 (0.0%), 4 (5.1%), 41 (52.5%), 25 (32.1%), and 8 (10.3%) patients exhibited CR, PR, SD, PD, and NE, respectively. Thus, the response and disease control rates were 5.7% and 64.3%, respectively.

Patient survival predictor

In the HAIC and sorafenib groups, the median survival time (MST) was 12.5 and 12.1 months, respectively (Fig 2A and 2B).

The prognostic factors of HAIC group are shown in Table 2, and five factors were significant predictors of survival in the univariate analysis: age < 70 (HR, 0.365; \( p = 0.003 \)), male sex (HR, 2.481; \( p = 0.014 \)), Child-Pugh A (HR, 0.461; \( p = 0.024 \)), a positive response (CR and PR, HR, 0.369; \( p = 0.004 \)), and conversion to sorafenib (HR, 0.409; \( p = 0.005 \)). In contrast, body composition measurement did not significantly affect OS. The MST of patients with muscle depletion was 15.8 months compared to 10.3 months for patients with no muscle depletion (\( p = 0.121 \), Fig 3A), while the MST of patients with H-VFA was 10.3 months compared to 13.2 months for patients with L-VFA (\( p = 0.371 \), Fig 3B). Furthermore, multivariate analysis identified positive response to HAIC (HR, 0.438; 95% CI at 0.200–0.892, \( p = 0.022 \)), and conversion to sorafenib (HR, 0.374; 95% CI at 0.183–0.767, \( p = 0.008 \)) as favorable prognostic factors.

In the sorafenib group, univariate analysis indicated that prognostic factors were Child-Pugh A (HR, 0.487; \( p = 0.018 \)), tumor number < 7 (HR, 0.494; \( p = 0.007 \)), absence of muscle depletion (HR, 0.506; \( p = 0.013 \)), and H-VFA (HR, 0.485; \( p = 0.009 \)). Furthermore, multivariate analysis identified tumor number < 7 (HR, 0.475; 95% CI at 0.273–0.822, \( p = 0.008 \)), absence of EHS (HR, 0.511; 95% CI at 0.295–0.877, \( p = 0.015 \)), absence of muscle depletion (HR, 0.555; 95% CI at 0.317–0.983, \( p = 0.044 \)), and H-VFA (HR, 0.483; 95% CI at 0.275–0.863, \( p = 0.015 \)), as shown in Table 3. Patients with no muscle depletion showed significantly longer survival than those with muscle depletion (MST 13.4 vs. 11.0 months, \( p = 0.010 \); Fig 4A). In addition,
patients with H-VFA also showed significantly longer survival than those with L-VFA (MST 15.0 vs. 8.4 months, \( p = 0.004 \); Fig 4B).

**Changes in body composition after HAIC or sorafenib treatment**

We analyzed the changes on SMI and VFA 3 months after the induction of each treatment. SMI decreased by 2.7% and 7.2% in HAIC and sorafenib groups, respectively (S1 Fig; \( p = 0.095 \)). However, comparison of VFA between both groups did not show significant changes at this time point.

**Discussion**

JSH recommends administration of HAIC as a first-line treatment for unresectable advanced HCC with portal invasion [10]; however, American or European professional organizations do not recommend it because of lack of evidence of survival benefits [6, 8]. Instead, the latter ones support systemic chemotherapy, including administration of sorafenib, a multi-targeted tyrosine kinase inhibitor (TKI) as a first treatment [6–10]. Therefore, it is necessary to identify patient characteristics that correlate with response to HAIC.

One characteristic of interest is sarcopenia, which was initially described as an age-related disorder; however, secondary sarcopenia has recently been linked to factors other than age and prognosis of various diseases, including cancer [12]. Indeed, skeletal muscle depletion is significantly associated with the prognosis of HCC [13–16, 26, 27].

In contrast, the predictive effect of VFA on the survival of patients with HCC is controversial [27–30]. Generally, obesity promotes carcinogenesis and cardiovascular disease [31, 32], and is associated with poor prognosis in several cancers. However, because these findings have been linked to strong observational bias, many investigators disagree with obesity being a predictive factor in the elderly or in patients with certain cancers [33–35].

| Table 2. Univariate and multivariate analyses of prognostic factors in patients treated with hepatic arterial infusion chemotherapy. |
|---------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Factors                                           | Univariate analysis |                  | Multivariate analysis |                  |                   |                   |
|                                                   | Hazard ratio        | 95%CI              | P value              | Hazard ratio        | 95%CI              | P value              |
| Age (< 70/\(\geq\) 70)                           | 0.365               | 0.187–0.702        | 0.003                | 0.572               | 0.271–1.177        | 0.130                |
| Sex (M/F)                                        | 2.481               | 1.188–5.849        | 0.014                | 1.716               | 0.786–4.188        | 0.182                |
| Child-Pugh class (A/B)                           | 0.461               | 0.246–0.897        | 0.024                | 0.601               | 0.279–1.300        | 0.194                |
| Tumor number (< 10/\(\geq\) 10)                 | 1.425               | 0.762–2.789        | 0.272                |                   |                   |                     |
| Tumor size [mm] (< 70/\(\geq\) 70)              | 0.929               | 0.500–1.706        | 0.812                |                   |                   |                     |
| MVI (absence/presence)                           | 0.800               | 0.325–1.698        | 0.583                |                   |                   |                     |
| EHS (absence/presence)                           | 0.616               | 0.288–1.521        | 0.271                |                   |                   |                     |
| Response * (positive/negative)                   | 0.369               | 0.173–0.729        | 0.004                | 0.438               | 0.200–0.892        | 0.022                |
| Conversion to sorafenib (yes/no)                 | 0.409               | 0.216–0.762        | 0.005                | 0.374               | 0.183–0.767        | 0.008                |
| Muscle depletion b (absence/presence)            | 1.647               | 0.884–3.190        | 0.118                |                   |                   |                     |
| VFA c (high/low)                                 | 1.329               | 0.719–2.333        | 0.368                |                   |                   |                     |

M, Male; F, Female; MVI, Macrovascular invasion; EHS, Extrahepatic spread; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; NE, No evaluation; SMI, Skeletal muscle index; VFA, Viscera fat area

* Evaluated by modified RECIST; Response (positive), CR & PR; Response (negative), SD & PD

b According to the criteria of Japan Society of Hepatology

c According to the criteria for ‘obesity disease’ as established by the Japan Society for the Study of Obesity

https://doi.org/10.1371/journal.pone.0218136.t002
We previously performed an integration analysis between skeletal muscle and visceral fat, which indicated that the body composition characteristic of no muscle depletion with H-VFA was a favorable survival predictor in patients treated with sorafenib [16]. In fact, both sorafenib

![Cumulative survival rates of patients treated with hepatic arterial infusion chemotherapy based on body composition.](https://doi.org/10.1371/journal.pone.0218136.g003)

**Fig 3.** Cumulative survival rates of patients treated with hepatic arterial infusion chemotherapy based on body composition. (a) Patients with or without muscle depletion. There were no significant differences between patients with or without muscle depletion (median survival time [MST], 15.8 vs. 10.3 months, \( p = 0.121 \)). (b) Patients with high-visceral fat (H-VFA) and low-visceral fat (L-VFA). There were no significant differences between the patients with H-VFA and L-VFA (MST, 10.3 vs. 13.2 months, \( p = 0.371 \)).

https://doi.org/10.1371/journal.pone.0218136.t003

| Factors                                         | Univariate analysis | Multivariate analysis |
|-------------------------------------------------|---------------------|-----------------------|
|                                                 | Hazard ratio | 95%CI | \( P \) value | Hazard ratio | 95%CI | \( P \) value |
| Age (< 70/\( \geq \) 70)                       | 0.775        | 0.452 – 1.295 | 0.335         | 0.655        | 0.374 – 1.187 | 0.159         |
| Sex (M/F)                                       | 1.656        | 0.938 – 2.817 | 0.081         | 0.535        | 0.286 – 1.028 | 0.060         |
| Child-Pugh class (A/B)                          | 0.487        | 0.283 – 0.880 | 0.018         | 0.475        | 0.273 – 0.822 | 0.008         |
| Tumor number (< 7/\( \geq \) 7)                | 0.494        | 0.294 – 0.821 | 0.007         | 0.475        | 0.273 – 0.822 | 0.008         |
| Tumor size [mm] (< 40/\( \geq \) 40)           | 0.682        | 0.411 – 1.126 | 0.135         | 0.511        | 0.295 – 0.877 | 0.015         |
| MVI (absence/presence)                         | 0.688        | 0.384 – 1.310 | 0.243         |              |              |              |
| EHS (absence/presence)                         | 0.637        | 0.383 – 1.060 | 0.082         | 0.511        | 0.295 – 0.877 | 0.015         |
| Disease control a (positive/negative)           | 0.612        | 0.353 – 1.077 | 0.088         |              |              |              |
| Response b (positive/negative)                  | 0.425        | 0.069 – 1.378 | 0.176         |              |              |              |
| Conversion to HAIC (yes/no)                    | 0.534        | 0.162 – 1.301 | 0.184         |              |              |              |
| Muscle depletion c (absence/presence)           | 0.506        | 0.300 – 0.864 | 0.013         | 0.555        | 0.317 – 0.983 | 0.044         |
| VFA d (high/low)                                | 0.485        | 0.289 – 0.831 | 0.009         | 0.483        | 0.275 – 0.863 | 0.015         |

M, Male; F, Female; MVI, Macrovascular invasion; EHS, Extrahepatic spread; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; NE, No evaluation; SMI, Skeletal muscle index; VFA, Viscera fat area

a Evaluated by modified RECIST; Response (positive), CR & PR; Response (negative), SD & PD

b Evaluated by modified RECIST; Disease control (positive), CR & PR & SD; Disease control (negative), PD

c According to the criteria of Japan Society of Hepatology

d According to the criteria for ‘obesity disease’ as established by the Japan Society for the Study of Obesity

https://doi.org/10.1371/journal.pone.0218136.t003
and HAIC have been often applied as a sequential chemotherapy regimen in Japan. However, there are no studies of body composition in patients treated with HAIC. Therefore, during the same period, we assessed prognostic factors related to HAIC and sorafenib therapy, including body composition by adding radiological disease control, response, and therapeutic conversion.

In the present study, body composition significantly affected the prognosis of sorafenib-treated patients with HCC, as a difference with HAIC-treated patients with HCC (Figs 2 and 3, Tables 2 and 3). Therefore, body composition may be a useful biomarker to identify patients with HCC who are likely to benefit from either HAIC or sorafenib.

Although the reasons why body composition has a different effect between the two treatments remain unclear, sorafenib therapy reduced skeletal muscle mass compared to HAIC (median, –7.2 vs. –2.7%; \( p = 0.095 \)). This result indicated that sufficient skeletal muscle mass was required for patients to complete the sorafenib therapy, compared to HAIC therapy. As patients with advanced HCC suffer from severe energy malnutrition regardless of having Child-Pugh A [36], a severe progression of muscle loss may contribute to a negative prognosis in sorafenib-treated patients with muscle depletion. Furthermore, such patients may require a certain amount of visceral fat as an energy substrate because of insufficient skeletal muscle mass. Consequently, H-VFA may be associated with a positive prognosis in this group. Therefore, we attribute the difference in changes of skeletal muscle mass between both treatments to a difference in pharmacological effects. Specifically, sorafenib suppressed tumor growth over a long duration of administration, whereas HAIC showed tumoricidal activity during a comparatively short-term administration.

The success of sorafenib, regorafenib, lenvatinib, cabozantinib, ramucirumab, and immune checkpoint inhibitors may change the treatment paradigm in patients with intermediate stage and advanced HCC [37]. For intermediate HCC [the so-called Barcelona clinic liver cancer (BCLC) stage B], TACE is the preferred first-line treatment according to guidelines for HCC [6–10]. However, because patients with intermediate stage HCC become refractory to repeated

---

**Fig 4. Cumulative survival rate of sorafenib-treated patients based on body composition.** (a) Patients with or without muscle depletion. Patients without muscle depletion showed significantly longer survival rate than those with muscle depletion (median survival time [MST], 13.4 vs. 11.0 months, \( p = 0.010 \)). (b) Patients with a high visceral fat area (H-VFA) and low visceral fat area (L-VFA). Patients with H-VFA also showed significantly longer survival rate than those with L-VFA (MST, 15.0 vs. 8.4 months, \( p = 0.004 \)).

https://doi.org/10.1371/journal.pone.0218136.g004
TACE procedures and liver function declines, conversion to sorafenib is initiated to improve the prognosis [38–40]. Maintaining hepatic function is important for improving the prognosis of patients with intermediate HCC because TKIs are generally used in patients with Child-Pugh A HCC. In the future, determination of TACE refractory status would increase the therapeutic options, such as TKIs, immune checkpoint inhibitors, and several combination therapies. However, HAIC treatment did not significantly deteriorate liver function compared to sorafenib [41], but significantly improved the Child-Pugh score of HAIC responders with Child-Pugh B HCC [42, 43]. In addition, patients with Child-Pugh B HCC were candidates for HAIC [9, 10]. Therefore, HAIC may be considered an important alternative treatment because there was a difference in survival between patients under HAIC and sorafenib treatments based on body composition.

Furthermore, multivariate analysis identified positive response to HAIC and conversion to sorafenib as independent prognostic factors. The considerable survival benefit of HAIC has been reported in HAIC responders [44–46]. Interestingly, our study showed that conversion to sorafenib in patients receiving HAIC was a stronger prognostic factor than positive response because of the lower HR. There are few reports on conversion to sorafenib in HAIC non-responders [47, 48].

Miyaki, et al. [47] reported that conversion to sorafenib in HAIC non-responders was a significant prognostic factor in a retrospective cohort study, but this study was limited by the different observation periods between conversion from the HAIC to the sorafenib group and the HAIC alone group. The same research group also conducted a prospective study, but it included only a single arm and considered a small sample size in a narrow observation period [48]. Our study also demonstrated the significant survival benefit of conversion to sorafenib in patients with advanced HCC regardless of the response to HAIC. The MST was significantly longer in patients with conversion to sorafenib than in those without conversion to sorafenib (16.5 vs. 7.1 months, \( p = 0.004 \); S2A Fig), although, there were no significant differences in patient characteristics except for Child-Pugh class (S2A Table). This observation suggested that conversion to sorafenib rescued a subset of HAIC non-responders from poor prognosis; therefore, it is important to identify patients who are likely to benefit from this strategy early in the HAIC treatment process.

In contrast, therapeutic conversion to HAIC was not identified as a prognostic factor in patients with HCC treated with sorafenib (S2B Fig and Table 2B). However, it is impossible to draw a conclusion from the present study because a small population of patients with therapeutic conversion was used; therefore, further investigations are required.

Finally, we combined the findings of this study with our previously developed scoring system for HAIC treatment [43, 49] to propose a guide as a treatment strategy for advanced HCC (Fig 5). We have reported the ACTH (Assessment for Continuous Treatment with HAIC) score as the scoring system which evaluated the response to HAIC at the mid-cycle of HAIC [49]. The ACTH score (range, 0–3) was calculated based on three parameters: Child-Pugh class (A = 0, B = 1), AFP response (yes = 0, no = 1), and DCP response (yes = 0, no = 1). A positive response of tumor marker was defined as a reduction of ≥ 20% for the baseline to the mid-cycle of HAIC (2 weeks after HAIC induction). Thus, based on the ACTH score, patients were divided into two groups: ≤ 1 vs. ≥ 2 points; MST, 15.1 vs. 8.7 months; \( p = 0.003 \) [49], which was further validated for therapeutic assessment [43]. We considered to continue HAIC treatment for patients with a score ≤ 1 and to initiate other treatments for patients with a score ≥ 2. Our draft proposal for a treatment strategy for advanced HCC is as follows: (1) Body composition of patients with Child-Pugh A HCC should be evaluated. Patients having no muscle depletion with H-VFA should select sorafenib and regorafenib as the first and second-line treatments, respectively. If patients have other body compositions, HAIC should be
selected as the first-line treatment. Furthermore, for patients with Child-Pugh B HCC, the first-line treatment should be HAIC. (2) After mid-course treatment of HAIC (i.e., 2 weeks), ACTH score can be evaluated [43, 49], which is likely to increase the number of candidates for sorafenib treatment, and might allow the use of sorafenib earlier in the treatment of HCC non-responders. When used in combination, the evaluation of body composition and the ACTH score may vastly improve patient survival. Furthermore, this is the first report of HCC treatment algorithm using an assessment of body composition. As the body composition quantitatively assessed the treatment performance, it may become an effective alternative to determine performance status, which is included in the BCLC system for HCC [6–8]. It has been reported that analytic morphomics, which uses semi-automated high-throughput CT image to measure body composition, is a useful approach to predict survival in patients with HCC [50]. This novel technique may provide further prognostic information.

The present study has some limitations. As this was a retrospective, and single-center study with a small population, further investigations, including a validation study with larger sample size, are necessary. In conclusion, body composition such as skeletal muscle and visceral fat was not identified as a prognostic factor for advanced HCC patients treated with HAIC. However, body composition may be a useful biomarker for the identification of patients with advanced HCC likely to experience survival benefits from sorafenib treatment. Additionally, our data suggest that the conversion to sorafenib in patients receiving HAIC may improve
survival, regardless of response to HAIC treatment. The inclusion of a strategy that efficiently incorporates both HAIC and sorafenib in patients with advanced HCC has the potential to significantly improve patient survival.

Supporting information

S1 Fig. Changes of skeletal mass index after HAIC or sorafenib treatment.
(TIF)

S2 Fig. Cumulative survival rates. (a) HAIC-treated patients with or without conversion to sorafenib. (b) Sorafenib-treated patients with or without conversion to HAIC.
(TIF)

S1 File. Minimal data set underlying the results.
(XLSX)

S1 Table. Therapeutic response to HAIC and sorafenib.
(DOCX)

S2 Table. Patients’ characteristics treated with HAIC or sorafenib. (a) HAIC-treated patients with or without conversion to sorafenib. (b) Sorafenib-treated patients with or without conversion to HAIC.
(DOCX)

Author Contributions

Conceptualization: Isao Sakaida.

Data curation: Masaki Maeda, Takuro Hisanaga, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa.

Formal analysis: Issei Saeki.

Investigation: Issei Saeki, Takahiro Yamasaki.

Supervision: Takahiro Yamasaki, Isao Sakaida.

Validation: Taro Takami.

Visualization: Taro Takami.

Writing – original draft: Issei Saeki.

Writing – review & editing: Isao Sakaida.

References

1. GLOBOCAN 2018. Available from: https://www.uicc.org/new-global-cancer-data-globocan-2018.

2. Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA, Bray F. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 2017. Epub 2017/08/31. https://doi.org/10.1002/hep.29498 PMID: 28859220; PubMed Central PMCID: PMCPMC5832532.

3. Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J Gastroenterol. 2019; 54(4):367–76. Epub 2018/11/29. https://doi.org/10.1007/s00535-018-1532-5 PMID: 30498904; PubMed Central PMCID: PMCPMC6437291.

4. Urata Y, Yamasaki T, Saeki I, Iwai S, Kitahara M, Sawai Y, et al. Clinical characteristics and prognosis of non-B non-C hepatocellular carcinoma patients with modest alcohol consumption. Hepatol Res. 2015. https://doi.org/10.1111/hepr.12572 PMID: 26288059.
5. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, et al. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg. 2015; 261(3):513–20. https://doi.org/10.1097/SLA. 0000000000000821 PMID: 25072437.

6. easloffice@easloffice.eu EASlSotLEa, Liver EASlSot. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018. Epub 2018/04/05. https://doi.org/10.1016/j.jhep.2018.03. 019 PMID: 29628281.

7. Verslype C, Rosmorduc O, Rougier P, Group EGW. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vi1–8. https://doi.org/10.1093/annonc/mds225 PMID: 22997453.

8. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecasis MM, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723–50. https://doi.org/10.1002/hep.29913 PMID: 29624689.

9. Kudo M, Matsu O, Izumi N, Iijima H, Kadoya M, Imai Y, et al. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014; 3(3–4):458–68. https://doi.org/10.1159/000343875 PMID: 26280007; PubMed Central PMCID: PMCPMC4531423.

10. Japan Society of Hepatology. Clinical Practice Guidelines for Hepatocellular Carcinoma (2017 version). Tokyo, Japan: Kanehara; 2017.

11. Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, et al. Effect of hepatic arterial infusion chemotheraphy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer. 2013; 109(7):1804–7. https://doi.org/10.1038/ bjc.2013.542 PMID: 24088659; PubMed Central PMCID: PMCPMC3790188.

12. Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc. 2016; 75(2):188–98. Epub 2016/01/08. https://doi.org/10.1017 /S0029665115004279 PMID: 26743210.

13. Hiraoka A, Hirooka M, Koizumi Y, Izumoto H, Ueki H, Kaneto M, et al. Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2017; 47(6):558–65. Epub 2016/08/30. https://doi.org/10.1111/hepr.12780 PMID: 27480045.

14. Imai K, Takai K, Hanai T, Ideta T, Miyazaki T, Kochi T, et al. Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib. Int J Mol Sci. 2015; 16(5):9612–24. https://doi.org/10.3390/ijms16059612 PMID: 25927982; PubMed Central PMCID: PMCPMC4463608.

15. Nishikawa H, Nishiijima N, Enomoto H, Sakamoto A, Komekado H, et al. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol Lett. 2017; 14(2):1637–47. Epub 2017/05/31. https://doi.org/10.3892/ol.2017.6287 PMID: 28789390; PubMed Central PMCID: PMCPMC5529937.

16. Saeki I, Yamasaki T, Maeda M, Kawano R, Hisanaga T, Iwamoto T, et al. No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma. Liver Cancer. 2018; 7(4):359–71. Epub April 6, 2018. https://doi.org/10.1159/000487858 PMID: 30488024

17. Arai S, Sata M, Sakamoto M, Shima M, Kumada T, Shinya S, et al. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010; 40(7):667–85. https://doi.org/10.1111/j.1872-034X.2010.00673.x PMID: 20633193.

18. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011; 29(3):339–64. https://doi.org/10.1159/ 000327577 PMID: 21829027.

19. Kudo M, Kitano M, Sakura T, Nishida N. General Rules for the Clinical and Pathologic Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan. Dig Dis. 2015; 33(6):765–70. https://doi.org/ 10.1159/000439101 PMID: 26488173.

20. Yamasaki T, Kurokawa F, Takami T, Omori K, Kawaguchi K, Tsuchiya M, et al. Arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and isosorbin for patients with advanced hepatocellular carcinoma, pilot study: Is a high dose of the biochemical modulator effective? Hepatol Res. 2003; 27(1):36–44. S1386634603001955 [pii]. PMID: 12957205.

21. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985). 1998, 85(1):115–22. https://doi.org/10.1152/jappl.1998.85.1.115 PMID: 9655763.
22. Yoshizumi T, Nakamura T, Yamane M, Islam AH, Menju M, Yamasaki K, et al. Abdominal fat: standardized technique for measurement at CT. Radiology. 1999; 211(1):283–6. https://doi.org/10.1148/radiology.211.1.99Apr15283 PMID: 10189485.

23. Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 2016; 46(10):951–63. https://doi.org/10.1111/hepr.12774 PMID: 27481650.

24. Hiuge-Shimizu A, Kishida K, Funahashi T, Ishizaka Y, Oka R, Okada M, et al. Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-study). Ann Med. 2012; 44(1):82–92. Epub 2010/10/22. https://doi.org/10.3109/07853890.2010.526138 PMID: 20964583.

25. Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012; 118(1):147–56. Epub 2011/06/28. https://doi.org/10.1002/cncr.26255 PMID: 21713764.

26. Meza-Junco J, Montano-Loza AJ, Baracos VE, Prado CM, Bain VG, Beaumont C, et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol. 2013; 47(10):861–70. https://doi.org/10.1097/MCG.0b013e318293a825 PMID: 23751844.

27. Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Watadani T, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015; 63(1):131–40. https://doi.org/10.1016/j.jhep.2015.02.031 PMID: 25724366.

28. Itoh S, Shirabe K, Matsumoto Y, Yoshiya S, Muto J, Harimoto N, et al. Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma. Ann Surg Oncol. 2014; 21(9):3063–8. https://doi.org/10.1246/s10434-014-3686-6 PMID: 24719020.

29. Higashi T, Hayashi H, Kaida T, Arima K, Takeyama H, Taki K, et al. Prognostic Impact of Visceral Fat Amount and Branched-Chain Amino Acids (BCAA) in Hepatocellular Carcinoma. Ann Surg Oncol. 2015; 22 Suppl 3:S1041-7. https://doi.org/10.1245/s10434-015-4796-5 PMID: 26305023.

30. Nault JC, Pigneur F, Nelson AC, Costentin C, Tselikas L, Katsahian S, et al. Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. Dig Liver Dis. 2015; 47(10):869–76. Epub 2015/07/10. https://doi.org/10.1016/j.dld.2015.07.001 PMID: 26211871.

31. Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev. 2015; 95(3):727–48. https://doi.org/10.1152/physrev.00030.2014 PMID: 26084689; PubMed Central PMCID: PMCPMC4491542.

32. Molica F, Morel S, Kwak BR, Rohner-Jeanrenaud F, Steffens S. Adipokines at the crossroad between obesity and cardiovascular disease. Thromb Haemost. 2015; 113(3):553–66. Epub 2014/10/23. https://doi.org/10.1152/physrev.00030.2014 PMID: 25338625.

33. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med. 1998; 338(1):1–7. https://doi.org/10.1056/NEJM199801013380101 PMID: 9414324.

34. Park Y, Peterson LL, Colditz GA. The Plausibility of Obesity Paradox in Cancer-Point. Cancer Res. 2018; 78(8):1898–903. https://doi.org/10.1158/0008-5472.CAN-17-3043 PMID: 29654151; PubMed Central PMCID: PMCPMC5903573.

35. Cospedes Feliciano EM, Kroenke CH, Caan BJ. The Obesity Paradox in Cancer: How Important Is Muscle? Ann Rev Nutr. 2018. Epub 2018/05/04. https://doi.org/10.1146/annurev-nutr-082117-051723 PMID: 29727593.

36. Harima Y, Yamasaki T, Hamabe S, SaeKI I, Okita K, Terai S, et al. Effect of a late evening snack using branched-chain amino acid-enriched nutrients in patients undergoing hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatol Res. 2010; 40(6):574–84. https://doi.org/10.1111/j.1872-034X.2010.00665.x PMID: 20618455.

37. Kudo M. Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma. Liver Cancer. 2018; 7(1):1–19. Epub 2018/02/15. https://doi.org/10.1159/000487148 PMID: 29662829; PubMed Central PMCID: PMCPMC5892376.

38. Hiraoka A, Kumada T, Kudo M, Hirooka M, Koizumi Y, Hiasa Y, et al. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. Dig Dis. 2017; 35(6):602–10. Epub 2017/10/17. https://doi.org/10.1159/000480256 PMID: 29040999.

39. Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, et al. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage
40. Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology. 2014; 87(6):330–41. https://doi.org/10.1159/000365993 PMID: 25227534.

41. Terashima T, Yamashita T, Arai K, Kawaguchi K, Kitamura K, Sakai Y, et al. Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma. Liver Cancer. 2017; 6(3):236–49. Epub 2017/05/17. https://doi.org/10.1159/000472262 PMID: 28626734; PubMed Central PMCID: PMCPMC5473075.

42. Terashima T, Yamashita T, Arai K, Kawaguchi K, Kitamura K, Sakai Y, et al. Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. Cancer Sci. 2016; 107(9):1263–9. Epub 2016/09/01. https://doi.org/10.1111/cas.12992 PMID: 27315783; PubMed Central PMCID: PMCPMC5021040.

43. Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, et al. Evaluation of the “assessment for continuous treatment with hepatic arterial infusion chemotherapy” scoring system in patients with advanced hepatocellular carcinoma. Hepatol Res. 2017. Epub 2017/06/28. https://doi.org/10.1111/hepr.12932 PMID: 28656680.

44. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006; 106(9):1990–7. https://doi.org/10.1002/cncr.21832 PMID: 16565970.

45. Nizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, Iwamoto H, et al. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol. 2012; 47(6):886–95. https://doi.org/10.1007/s00535-012-0555-6 PMID: 22382631.

46. Miyaki D, Aikata H, Honda Y, Naeshiro N, Nakahara T, Tanaka M, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. J Gastroenterol Hepatol. 2012; 27(12):1850–7. https://doi.org/10.1111/j.1440-1746.2012.07276.x PMID: 23020312.

47. Miyaki D, Aikata H, Kan H, Fujino H, Urabe A, Masaki K, et al. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. J Gastroenterol Hepatol. 2013; 28(12):1834–41. https://doi.org/10.1111/j.1440-1746.2013.07451.x PMID: 23808713.

48. Hatooka M, Kawaoaka T, Aikata H, Inagaki Y, Morio K, Nakahara T, et al. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. BMC Cancer. 2018; 18(1):633. Epub 2018/06/04. https://doi.org/10.1186/s12885-018-4519-y PMID: 29866075; PubMed Central PMCID: PMC5897491.

49. Saeki I, Yamasaki T, Tanabe N, Iwamoto T, Matsumoto T, Urata Y, et al. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy. PLoS One. 2015; 10(5):e0126649. https://doi.org/10.1371/journal.pone.0126649 PMID: 25992784; PubMed Central PMCID: PMCPMC4439162.

50. Singal AG, Zhang P, Waljee AK, Ananthakrishnan L, Parikh ND, Sharma P, et al. Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma. Clin Transl Gastroenterol. 2016; 7:e172. Epub 2016/05/26. https://doi.org/10.1038/ctg.2016.31 PMID: 27228403; PubMed Central PMCID: PMCPMC4893682.